Screener
Maze Therapeutics MAZE Total Revenue
Total Revenue at other companies
Segments
By geography
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Maze Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:11 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219430
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| License revenue | $20,000 | — |
| Operating expenses: | ||
| Research and development | 34,148 | 27,580 |
| General and administrative | 12,405 | 7,821 |
| Total operating expenses | 46,553 | 35,401 |
| Loss from operations | (26,553) | (35,401) |
| Other income (expense): | ||
| Interest and other income, net | 3,211 | 2,615 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Maze Therapeutics's total revenue?
- Maze Therapeutics (MAZE) reported total revenue of $20M in Q1 2026.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Maze Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude